Skip to main content

Dr. Michael J. Hall, M.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
27
In the NPI registry since
2006
Medicare patients seen, 2024
228

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1999Medical school: Columbia University College of Physicians and Surgeons
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    PA license MD435434

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
228
Services billed
374
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes11370
Established patient office or other outpatient visit, 40-54 minutes10250
Established patient office or other outpatient visit, 20-29 minutes3434
New patient office or other outpatient visit, 15-29 minutes1515
New patient office or other outpatient visit, 60-74 minutes1414
New patient office or other outpatient visit, 30-44 minutes1212

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 19 payments worth $4,495 in total to this clinician.

By type
Consulting Fee$3,425
Food and Beverage$563
Travel and Lodging$507

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 15, 2025Incyte Corporation
May 15, 2025
Consulting Fee
ZYNYZ · Oncology
$2,740
Oct 16, 2025Incyte Corporation
Oct 16, 2025
Consulting Fee
Zynyz · Oncology
$685
May 10, 2025Incyte Corporation
May 10, 2025
Travel and Lodging
ZYNYZ · Oncology · travel to Philadelphia, PA
$254
May 10, 2025Incyte Corporation
May 10, 2025
Travel and Lodging
ZYNYZ · Oncology · travel to Philadelphia, PA
$254

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $133,081 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Ch…
    Janssen Research & Development, LLC
  • A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
    Janssen Research & Development, LLC
  • POA Retrospective Repository
    Caris Mpi, Inc. · Status unknown · NCT03326479

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Philadelphia

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 9, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1811941644. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.